期刊文献+

环磷酰胺冲击治疗狼疮肾炎的临床研究 被引量:1

Clinical study of CTX pulse treatment on lupus nephritis
下载PDF
导出
摘要 目的通过临床对比研究,探讨应用环磷-酰胺冲击治疗(IV-CTX)狼疮肾炎(LN)的最佳方案。方法将92例LN患者随机分成3组:A组,IV-CTX每2周1次,每次(8~12)mg/kg,连用2天,B组,IV-CTX每月1次,每次(0.5~1.0)g/m2;C组,IV-CTX每3个月1次,每次(0.5~1.0)g/m2。3组均同时口服波尼松。结果A组起效时间显著比B组与C组快;病情缓解率A组也显著高于B组及C组(P<0.01);病情活动性积分下降至25%、50%和75%时,3组CTX累积量无显著差异(P>0.05);3组间不良反应及其发生率无显著统计学差异(P>0.05)。结论IV-CTX治疗LN应根据狼疮活动程度选择。在急重症LN,应用A组2周1次方案有利于及时控制狼疮活动,提高疗效,保护肾功能;在LN病情基本控制后,改用B组每月1次方案可以巩固疗效;在LN病情完全控制后,应用C组3个月1次方案可以预防复发。 To investigate the best method of CTX pulse therapy(IV-CTX) on lupusnephritis (LN). Methods 92 cases of LN were divided into three groups randomly. Group A: Two-dayIV-CTX (8~12mg/kg. d) every two weeks; Group B: IV-CTX (O.5~1.0g/m2)once a month; GroupC: IV-CTX(0. 5~1. 0g/m2) every three months. Prednisone was a basical treatment in each group. Results The time taking effect in group A was shortest, and also had the most significant remission rate(P<0. 01). There was no significant difference of CTX accumulative quantity among three groupswhen disease activity score decreased to 25%,50% and 75%, and there was no significant difference among three groups in side effect either (P>0.05). Conclusion A reasonable IV-CTX should be chosenaccording to the disease activity.
出处 《中国全科医学》 CAS CSCD 1999年第5期365-367,共3页 Chinese General Practice
关键词 环磷酰胺 冲击疗法 狼疮性肾炎 CTX Pulse treatment Lupus nephritis
  • 相关文献

参考文献2

二级参考文献1

共引文献61

同被引文献14

  • 1Fabbri P,Cardinali C,Giomi B.Cutaneous lupus erythematosus:diagnosis and management[J].Am J Clin Dermatol,2003,4(7):449-465
  • 2Chieregato C,Barba A,Zini A.Discoid lupus erythematosus:clinical and pathological study of 24 patients[J].J Eur Acad Dermatol Venereol,2004 18(1):113
  • 3Kundig TM,Trueb RM,Krasovec M.Lupus profundus / panniculitis[J].Dermatology,1997,195(1):99-101
  • 4Lee LA.Neonatal lupus:clinical features,therapy,and pathogenesis[J].Curr Rheumatol Rep,2001,3(5):391-395
  • 5Tam LS,Li EK,Szeto CC,et al.Treatment of membranous lupus nephrits with prednisone,azathioprine and cyclosporin A[J].Lupus,2001,11:827-829
  • 6Perez C,Guarch R,Rodrigo M,et al.Successful treatment of leucocytoclastic vasculitis and pancytopenia secondary to systemic lupus erythematosus with intravenous immunoglobulin[J].Br J Dermatol,2002,147 (1):180-182
  • 7Mok CC,Lau CS,Wong RW.Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance:an open-label study[J].Am J Med,2003,115(1):59-62
  • 8Mok CC,Lai KN.Mycophenolate mofetil in lupus glomerulonephritis[J].Am J Kidney Dis,2002,40(3):447-457
  • 9Matthews SJ,McCoy C.Thalidomide:a review of approved and investigational uses[J].Clin Ther,2003,25(2):342-395
  • 10Lindskov R,Reymann F.Dapsone in the treatment of cutaneous lupus erythematosus[J].Dermatologica,1986,172 (4):214-217

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部